Valuation: Genmab A/S

Market Cap 223B 32.91B 29.87B 27.6B 24.9B 47B 3,075B 48.8B 333B 132B 1,659B 123B 121B 5,242B P/E 2026 *
41.9x
P/E 2027 * 32.7x
Enterprise Value 242B 35.7B 32.41B 29.94B 27.01B 50.98B 3,335B 52.94B 361B 143B 1,800B 134B 131B 5,686B EV / Sales 2026 *
8.08x
EV / Sales 2027 * 6.47x
Free-Float
94.31%
Yield 2026 *
-
Yield 2027 * -
1 day-0.77%
1 week-2.21%
Current month-10.48%
1 month+37.77%
3 months+66.44%
6 months+107.16%
Current year+72.77%
1 week 3,423
Extreme 3423
3,625
1 month 2,473
Extreme 2473
3,947
Current year 1,512
Extreme 1512
3,947
1 year 1,512
Extreme 1512
3,947
3 years 1,157
Extreme 1157
3,947
5 years 1,157
Extreme 1157
3,947
10 years 786.2
Extreme 786.2
3,947
Manager TitleAgeSince
Chief Executive Officer 65 01/06/2010
Director of Finance/CFO 48 01/03/2020
Chief Tech/Sci/R&D Officer - 16/08/2024
Director TitleAgeSince
Director/Board Member 75 01/11/2003
Director/Board Member 58 01/01/2015
Director/Board Member 75 01/01/2015
Date Insider Type Main position Quantity % Market Cap. Importance
01/12/25 Exercice

Director

189 0.0003%
01/12/25 Exercice

Director

189 0.0003%
01/12/25 Exercice

Director

283 0.0004%
Change 5-day change 1-year change 3-year change Capi.($)
-0.77%-2.21%+77.27%+57.96% 32.9B
+1.15%-2.81%+53.73%+71.00% 65.56B
-2.64%-1.13%+7.82%+88.90% 60.41B
-1.07%+0.30%+22.91%+86.76% 55.76B
-0.32%-3.21%+8.97%+119.61% 46.98B
-1.91%-5.40%+20.44%+27.11% 43.63B
-0.70%+1.43%+14.05%+45.20% 36.7B
-1.83%-14.97%+137.42%+669.60% 36.09B
-1.05%+2.31%-38.07%+392.55% 26.96B
-0.94%-5.36%+38.96%-3.04% 24.45B
Average -1.00%-1.98%+34.35%+155.57% 43B
Weighted average by Cap. -0.94%-1.65%+33.83%+139.50%

Financials

2026 *2027 *
Net sales 29.99B 4.42B 4.01B 3.7B 3.34B 6.31B 413B 6.55B 44.64B 17.66B 223B 16.57B 16.23B 704B 36.34B 5.35B 4.86B 4.49B 4.05B 7.65B 500B 7.94B 54.1B 21.4B 270B 20.09B 19.66B 853B
Net income 5.33B 785M 713M 659M 594M 1.12B 73.37B 1.16B 7.94B 3.14B 39.59B 2.95B 2.88B 125B 7.05B 1.04B 942M 871M 785M 1.48B 96.99B 1.54B 10.49B 4.15B 52.34B 3.89B 3.81B 165B
Net Debt 18.93B 2.79B 2.53B 2.34B 2.11B 3.98B 261B 4.14B 28.19B 11.15B 141B 10.47B 10.24B 444B 11.78B 1.74B 1.58B 1.46B 1.31B 2.48B 162B 2.57B 17.54B 6.94B 87.53B 6.51B 6.38B 277B
Projected Income Statement - Annual - Genmab A/S
Logo Genmab A/S
Genmab A/S specializes in the research and development of human and therapeutic antibodies intended for treating cancers, infectious diseases, rheumatoid arthritis, etc. Net sales break down by type of income as follows: - royalties (83.4%); - income from sales of products (10.7%); - other (5.9%): primarily income from partnership agreement. Net sales are distributed geographically as follows: Denmark (89.4%), the United States (4.9%) and Japan (5.7%).
Employees
3,244
Date Price Change Volume
17/11/26 DKK 3,502.00 -0.77% 152,354
16/11/26 DKK 3,529.00 +2.35% 152,134
13/11/26 DKK 3,448.00 -2.32% 130,080
12/11/26 DKK 3,530.00 -0.87% 276,750
11/11/26 DKK 3,561.00 -0.56% 201,425
Trader
Investor
Global
Quality
ESG MSCI
A
MarketScreener Ratings - Genmab A/S
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
16
Last Close Price
3,529.00DKK
Average target price
4,195.23DKK
Spread / Average Target
+18.88%
  1. Stock Market
  2. Stocks
  3. GMAB Stock